Vivoryon Therapeutics NV to report full-year 2023 financial results and operational progress on April 24, 2024
Halle (Saale) / Munich, Germany, April 16th 2024 – Vivoryon Therapeutics NV (Euronext Amsterdam: VVY; NL00150002Q7) (Vivorillon), a clinical-stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced its full-year 2023 financial results and announced 4. announced that it will provide the latest company information on Mondays and Wednesdays. We will host public conference calls and webcasts. The report will be available for download from our website at https://www.vivoryon.com/investors-news/financial-information/.
Conference call details
Date: April 24, 2024
Time: 3:00 PM CEST / 9:00 AM EDT
Conference calls are available by phone and webcast.
A live audio webcast of the call will be available on Vivoryon's website at https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/.
To join the conference call by telephone, participants can pre-register and receive dedicated dial-in details to easily and quickly access the call at the following website:
https://register.vevent.com/register/BI3fef74de02dc40daa7cbe0aac7731e74
We recommend that participants dial into the conference call 15 minutes before the scheduled start time to avoid late attendance.
###
About Vivoryon Therapeutics NV
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by a passion for breakthrough science and innovation, we strive to transform the lives of patients in need with serious diseases. We leverage our deep expertise in understanding post-translational modifications to develop medicines that modulate protein activity and stability as they change in disease settings. In addition to valoglutamstat, the lead program in Phase 2 clinical development to treat Alzheimer's disease, orally available small molecules for a variety of indications include cancer, inflammatory diseases, and fibrosis. We have established a robust pipeline of inhibitors. www.vivoryon.com
Vivoryon's forward-looking statements
This press release contains forward-looking statements, including, without limitation, regarding Vivoryon Therapeutics NV's (the “Company”) business strategy, management plans and future operating objectives, estimates and projections regarding the Company's markets. It is. Predictions and statements about when our products will be available. “anticipate”, “believe”, “estimate”, “expect”, “predict”, “intend”, “may”, “plan”, “anticipate”, “anticipate”; Words such as “should”, “anticipate” and similar expressions in connection with the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance. Rather, they are based on management's current expectations and assumptions regarding future events and trends, economic and other future conditions, as well as estimates, forecasts and other statistical data made by independent third parties. Based on the evaluation conducted by. Forward-looking statements involve a number of known and unknown risks and uncertainties. These risks, uncertainties and other factors could materially and adversely affect the results and financial consequences of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied by such forward-looking statements or expectations. Accordingly, you should not place undue reliance on such forward-looking statements. This press release does not contain any risk factors. Certain risk factors that may affect our future financial results are discussed in our publicly available annual financial statements. This press release, including forward-looking statements, speaks only as of the date of this press release. We undertake no obligation to update the information or forward-looking statements contained herein, except as required by law to disclose such information.
For more information, please contact us below.
Investor contact information
Stern IR
Penelope Belknap
Phone: +1 212-362-1200
Email: penelope.belnap@sternir.com
media contact
trophy communications
Valeria Fisher
Phone: +49 175 8041816
Email: vivoryon@trophic.eu
